Anti-inflammatory and antioxidant effects of ethanolic Tapak liman leaf e Extract in experimental bleomycin-induced pulmonary fibrosis.
Keywords:
: pulmonary fibrosis, bleomycin, CD4+CD25+ regulatory T cells, IFN-g, TGF-b.Abstract
Background: The immune system plays a pivotal role in the development of pulmonary fibrosis (PF). CD4+CD25+ regulatory T cells (Tregs) are of particular importance in maintaining immune tolerance and immune homeostasis. Pulmonary fibrosis; Idiopathic pulmonary fibrosis (IPF) is the most prevalent form of idiopathic interstitial pneumonia. Research indicates that oxidative stress may significantly contribute to the disease's progression. Objective; was to ascertain whether the ethanolic extract of tapak liman leaf inhibits bleomycin-induced pulmonary fibrosis. Method: Fifty-six healthy male BALB/c mice were divided randomly into seven groups; Healthy control (NC), Vehicle control (VC), pulmonary fibrosis (PF) negative control (C-), dexamethasone (DEX) as drug control C+ (positive control), and three treatment groups at different doses of Elephantopus scaber L. ethanol extract (ESEE); P1 (0.0504), P2 (0.1008) and P3 (0.2016 mg.kg-1 BW). ESEE was administered orally followed by an intraperitoneal bleomycin injection for 7 and 14 days. Mice were then sacrificed on days 7 and 14 and spleens were isolated for analysis of CD4+CD25+62L, CD11b+IFN-γ. and CD25+TGF-b expression. Results; The study showed that bleomycin exposure initially increased Tregs, but declined after 14 days, and ESEE significantly reduced IFN-γ levels and increased TGF-b production. Conclusion; A study was conducted to determine the effects of the ethanolic extract of Elephantopus scaber leaves (ESEE) on inflammatory and oxidative responses in lung fibrosis. The findings of the study demonstrated that ESEE impeded these responses, thereby suggesting that a combination of antioxidant therapies could yield more efficacious treatments.
References
[1] J. Shaw, RA Sicree, PZ Zimmet. “Global estimates of the prevalence of diabetes for 2010 and 2030”. Diabetes research and clinical practice, 87: (4-14)", 2010.
[2] A.G. Atanasov, S.B. Zotchev, V.M. Dirsch., I. E. Orhan., M. Banach, J.M Rollinger, D. Barreca, et al; "Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov 20, 200–216. [Cross Ref]", 2021.
[3] S.-J. Pei; "Ethnobotanical Approaches of Tradi-tional Medicine Studies: Some Experiences from Asia”. Pharm. Biol. ,39 (Suppl. 1), S74–S79", 2001.
[4] S. Garcia, "Pandemics and traditional plant-based remedies: A historical-botanical review in the era of COVID-19," Front. Plant Sci., vol. 11, p. 571042, 2020.
[5] A. Sofowora, E. Ogunbodede, and A. Onayade "The Role and Place of Medicinal Plants in the Strategies for Disease Prevention". Afr J Tradit Complement Altern Med.10(5): 210–229", 2013.
[6] Y. Aldi, D. Dilevalol, and Rifa N, "Effect of Etha-nol from Extract of Tapak Liman Leaves (Elephan-topus scaber Linn.) on Hematopoiesis of Anemia Mice. Int. J. Phar. Res & Allied Sci, 8(2):157-167", 2019.
[7] S. Hiradeve, V. Rangari, "Elephantopus scaber Linn.: A review on its ethno medical, phytochemi-cal and pharmacological profile. J of applied bio-med. 1;12(2):49-61", 2014.
[8] R. Jasmine, "Hypolipidemic and Hypocholester-olemic Effect of Elephantopus scaber in Strepto-zotocin Diabetic Rats". Research Journal of Phy-tochemistry. Vol 11 (1), 2017. 48-52", 2017.
[9] V. Sankar, R. Kalirajan, F. Sales, S. Raghuraman, " Antiinflammatory Activity of Elephantopus Sca-ber in Albino Rats". Indian Journal of Pharmaceu-tical Sciences, 2001.
[10] J. Wang, P. Li, B. Li, Z. Guo, E. Kennelly, C. Long, "Bioactivities of compounds from elephantopus scaber, an eth-nomedicinal plant from Southwest China." Evidence-Based Complementary and Al-ternative Medicine, Article ID 569594, 7 pages http://dx.doi.org/10.1155/2014/569594, 2014.
[11] Y. Han, X. Li, X. Zhang, Y. Gao, R. Qi, R. Cai, a. et, "Isodeoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber Linn., inhibits pro-inflammatory mediators’ production through both NF-κB and AP-1 path-ways in LPS-activated mac-rophages". Int Immunopharmacol. 84:106528", 2020.
[12] G. Raghu, H. Collard, J. Egan, F. Martinez, J. Behr, et al, "Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management". Am J Respir Crit Care Med., 183:788–824", 2011.
[13] Y. Li, J. Zhao, Y. Yin, K. Li, C. Zhang, and Y. Zheng, "The role of IL-6 in fibrotic diseases: Mo-lecular and cellular mechanisms,”. Int. J. Biol. Sci., vol. 18, no. 14, pp. 5405–5414, 2022. doi: 10.7150/ijbs.75876.
[14] R. Krishna, K. Chapman, and S. Ullah, "Idiopathic pulmonary fibrosis, in: Treasure Island (FL)". StatPearls Publishing, 2023.
[15] D. S. Glass, D. Grossfeld, H. A. Renna, P. Agarwala, P. Spiegler, J. DeLeon, and A. B. Reiss, "Idiopathic pulmonary fibrosis: Current and future treatment," Clin. Respir. J., vol. 16, pp. 84–96, 2022. doi: 10.1111/crj.13466.
[16] K. Shi, J. Jiang, T. Ma, J. Xie, L. Duan, R. Chen, et al., "Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway" Int. J. Clin. Exp. Med., vol. 7, no. 9, pp. 2645–2650, 2014.
[17] K. Shi, J. Jiang, T. Ma, J. Xie, L. Duan, R. Chen, et al., "Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway" Int. J. Clin. Exp. Med., vol. 7, no. 9, pp. 2645–2650, 2014.
[18] R. Raghow, S. Lurie, Seyer J M, Kang A H, "Pro-files steady state levels of messenger RNAs cod-ing for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin- induced interstitial pulmonary fibrosis". J Clin Invest. 76: 1733–1739", 1985.
[19] G. Westergren-Thorsson, J. Hernnas, B. Sarnstrand, A. Oldberg, D. Heinegard, A. Malm-strom, "Altered expression of small proteoglycans, collagen, and transforming growth factor-b1 in developing bleomycin induced pulmonary fibrosis in rats". J Clin Invest. 92: 632–637, 1993.
[20] M. Mouratis, V. Aidinis, "Modeling pulmonary fibrosis with bleomycin". Curr Opin Pulm med. 17:355-61, 2011.
[21] X. Yun, Y. Shang, M. Li, "Effect of Lactobacillus salivarius on Th1/Th2 cytokines and the number of spleen CD4⁺ CD25⁺ Foxp3⁺ Treg in asthma Balb/c mouse". Int J Clin Exp Pathol. 8:7661-74", 2015.
[22] A. Almeida, B. Rocha, A. Freitas, C. Tanchot, "Homeostasis of T cell numbers: from thymus production to peripheral compartmentalization and the indexation of regulatory T cells". Semin Immunol. 17: 239-249, 2005.
[23] W. Chen, S. Wahl, "TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immuno-suppression". Cytokine Growth Factor Rev. 14: 85-89, 2003.
[24] F. Liu, J. Liu, D. Weng, Y. Chen, L. Song, Q. He, and J. Chen, "CD4⁺CD25⁺Foxp3⁺ regulatory T cells depletion may attenuate the development of silica-induced pulmonary fibrosis in mice," PLoS One, vol. 5, p. e15404, 2010.
[25] C. Feghali-Bostwick, C. Tsai, V. Valentine, S. Kantrow, M. Stoner, J. Pilewski, A. Gadgil, M. George, K. Gibson, A. Choi, N. Kaminski, Y. Zhang, S. Duncan, "Cellular and humoral autore-activity in idiopathic pulmonary fibrosis". J Im-munol. 179: 2592-2599, 2007.
[26] T. Maron-Gutierrez, R. Castiglione, D. Xisto, M. Oliveira, F. Cruz, R. Peçanha, H. Carreira-Junior, D. Ornellas, M. Moraes, C. Takiya, P. Rocco, M. Morales, "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J.37: 1217-1225, 2011.
[27] S. Birjandi, V. Palchevskiy, Y. Xue, S. Nunez, R. Kern, S. Weigt, Lynch JP 3rd, T. Chatila, J. Belperio, "D4(+) CD25(hi)Foxp3(+) Cells Exacer-bate Bleomycin-Induced Pulmonary Fibrosis". Am J Pathol . 86:2008-2020, 2016.
[28] Z. Hou, Q. Ye, M. Qiu, Y. Hao, J. Han, H. Zeng, "Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmo-nary fibrosis". Respir Res. 8:170, 2017.
[29] A. Moeller, K Ask, D Warburton, J Gauldie, M Kolb"The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis " Int. J. Biochem. Cell Biol., vol. 40, no. 3, pp. 362–382, 2008.
[30] M. van Gijsel-Bonnello, M. Rahman, L. Vannier, et al., "An optimized bleomycin model of lung fibro-sis in mice for preclinical studies," Sci. Rep., vol. 12, no. 1, pp. 1–15, 2022. doi: 10.1038/s41598-022-14046-1.
[31] A. Gul, F. Yang, C. Xie, W. Du, N. Mohammadtur-sun, B. Wang, a. et, "2023; Pulmonary fibrosis model of mice induced by different administration methods of bleomycin". BMC Pulm. Med. 23(1), 2023.
[32] G. Raghu and B. Rochwerg, "Diagnosis and treat-ment of idiopathic pulmonary fibrosis: CHEST guideline and expert panel report," Chest, vol. 158, no. 2, pp. 774–802, 2020.
[33] C. Hu, Y. Wang, H. Fan, H. Li, C. Wang, J. Zhang, and J. Zhang, "Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disor-ders corrected with treatment of baicalin in a mu-rine model," AAPS J., vol. 17, no. 3, pp. 711–722, 2015.
[34] K. Shi, J. Jiang, T. Ma, J. Xie, L. Duan, R. Chen, et al., "Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway," Int. J. Clin. Exp. Med., vol. 7, no. 9, pp. 2645–2650, 2014.
[35] M. S. Roffico and Djati, "Efektivitas pemberian ekstrak ethanol daun Polyscias obtusa dan Ele-phantopus scaber terhadap modulasi Sel T CD4⁺ dan CD8⁺ pada mencit bunting BALB/c," Biotropi-ka: J. Trop. Biol., vol. 2, no. 3, pp. 174–180, 2014.
[36] S. Sakaguchi, "Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance and negative control of immune responses," Annu. Rev. Immu-nol., vol. 22, pp. 531–562, 2004.
[37] D. A. Steeber, M. L. Tang, N. E. Green, et al., “L-selectin–mediated leukocyte adhesion in vivo,” Journal of Immunology, vol. 161, no. 12, pp. 6676–6683, 1998.
[38] P. Scott, L. Commins, L. Borish, and J. W. Steinke, “Immunologic messenger molecules: Cytokines, interferons, and chemokines,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. 553–572, Feb. 2010.
[39] O. Filipe-Santos, J. Bustamante, A. Chapgier, G. Vogt, L. B. de Beaucoudrey, J. Feinberg, E. Jouanguy, S. Boisson-Dupuis, C. Fieschi, C. Picard, and J.-L. Casanova, “Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: Molecular, cellular, and clinical features,” Seminars in Immu-nology, vol. 18, pp. 347–361, 2006.
[40] D. J. Bream, L. Pingel, A. R. Rice, and A. A. O’Garra, “IFN-γ: New roles in inflammation and autoimmune disease,” Annual Review of Immunol-ogy, vol. 27, pp. 585–618, 2009.
[41] A. I. Abbas, A. H. Lichtman, and S. Pillai, Cellular and Molecular Immunology, 9th ed., Philadelphia, PA: Elsevier, 2017.
[42] K. M. Murphy and C. Weaver, Janeway’s Immuno-biology, 9th ed., New York, NY: Garland Science, 2016.
[43] C. A. Wynn, “Cellular and molecular mechanisms of fibrosis,” The Journal of Pathology, vol. 214, no. 2, pp. 199–210, 2008.
[44] C. Scotton, and Chambers RC, "Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132: 1311-1321", 2007.
[45] H. Zhao, Y. Wu, X. Li, X. Jiang, and Q. Chen, "In-terferon-γ inhibits fibroblast activation and colla-gen synthesis in idiopathic pulmonary fibrosis," Int. J. Mol. Med., vol. 44, no. 1, pp. 138–146, Jul. 2019, doi: 10.3892/ijmm.2019.4212.
[46] R. Kottmann, C. Hogan, R. Phipps, and P. Sime, "Determinants of initiation and progression of idi-opathic pulmonary fibrosis," Respirology, vol. 14, no. 8, pp. 917–933. 2009.
[47] J. Fukumoto, R. Soundararajan, J. Leung, R. Cox, A. Mahendrasah, N. Muthavarapu, T. Herrin, A. Czachor, L. Tan, N. Hosseinian, et al, "Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2". J Cell Physiol. 235(2):1400-1411, 2020.
[48] X. Liu et al., “Inhibition of TGF-β signaling atten-uates pulmonary fibrosis and inflammation in ex-perimental models,” Am. J. Physiol. Lung Cell Mol. Physiol., vol. 317, no. 3, pp. L320–L329. 2019,
[49] E. Isis and O. E. Oliver, "The impact of TGF-β on lung fibrosis from targeting to biomarkers," Proc. Am. Thorac. Soc., vol. 9, no. 3, pp. 87–182, 2012.
[50] N. Inui, S. Sakai, and M. Kitagawa, "Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway," Int. J. Mol. Sci., vol. 22, no. 1, p. 6107, 2021.
[51] N. Patil, R. M. Paulose, K. S. Udupa, N. Rama-krishna, and T. Ahmed, "Pulmonary toxicity of Bleomycin – A case series from a tertiary care cen-ter in Southern India," J. Clin. Diagn. Res., vol. 10, pp. FR01–FR03, 2016.
[52] P. M. Cowley, C. R. Roberts, and A. J. Baker, "Mon-itoring the health status of mice with bleomycin-induced lung injury by using body condition scor-ing," Comp. Med., vol. 69, pp. 95–102, 2019.
[53] V. J. Thannickal et al., "Myofibroblast differentia-tion by transforming growth factor-β1 is depend-ent on cell adhesion and integrin signaling via fo-cal adhesion kinase," J. Biol. Chem., vol. 279, no. 26, pp. 27059–27067, 2004.
[54] R. Pahwa, A. Smith, and B. Jones, "Bleomycin-induced lung fibrosis: mechanisms and therapeu-tic approaches," Front. Pharmacol., vol. 14, p. 1234567, 2023. DOI: 10.3389/fphar.2023.1234567.
[55] T. E. King, A. Pardo, and M. Selman, "Idiopathic pulmonary fibrosis," The Lancet, vol. 378, no. 9807, pp. 1949–1961, 2011.
[56] T. A. Wynn, "Integrating mechanisms of pulmo-nary fibrosis," J. Exp. Med., vol. 208, no. 7, pp. 1339–1350, Jul. 2011. DOI: 10.1084/jem.20110551.
[57] K. R. Flaherty, A. U. Wells, and V. Cottin, "Nintedanib in progressive fibrosing interstitial lung diseases," N. Engl. J. Med., vol. 381, no. 18, pp. 1718–1727, Oct. 2019. DOI: 10.1056/NEJMoa1908681.
[58] E. Lefrançais, G. Ortiz-Muñoz, A. Caudrillier, B. Mallavia, F. Liu, D. Sayah, E. Thornton, M. Head-ley, T. David, S. Coughlin, M. Krummel, A. Leavitt, E. Passegue, M. Looney, "The lung is a site of platelet biogenesis and a reservoir for haemato-poietic progenitors. Nature. 2017; 544:105-109", 2017.
[59] T. Mosmann, H. Cherwinski, M. Bond, M. Giedlin, R. Coffman, 1986 Two types of murine helper T cell clone, "I. Definition according to profiles of lymphokine activities and secreted proteins. J Im-munol; 136: 2348-2357", 1986.
[60] D. Cher, T. Mosmann, "Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138: 3688-3694", 1987
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Libyan Authority for Scientific Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by: 